(:LOGC)

Nov 14, 2022 07:00 am ET
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet
Oct 31, 2022 06:26 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 31, 2022 12:47 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SP
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 23, 2022 10:02 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCOR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Southern Missouri Bancorp, Inc....
Oct 20, 2022 10:45 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nas
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 18, 2022 11:29 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 18, 2022 07:30 pm ET
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 15, 2022 06:22 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: LogicBio Therapeutics, Inc. (NASDAQ:...
Oct 11, 2022 03:00 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, LOGC, OIIM, JVA
NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 07, 2022 08:00 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) CarLotz, Inc. (Nasdaq – LOTZ), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nas
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 04, 2022 02:00 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates POSH, FCRD, LOGC, TALO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Poshmark, Inc. (NASDAQ: POSH)’s sale...
Oct 04, 2022 11:40 am ET
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 04, 2022 11:10 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, POSH, SSNT
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 03, 2022 10:20 pm ET
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating LogicBio Therapeutics, Inc. (LOGC), relating to its proposed acquisition by AstraZeneca Rare Disease. Under the terms of the tender offer, LOGC shareholders will receive $2.07 in cash per share they own. Click here for more information: ht
Oct 03, 2022 04:47 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LogicBio Therapeutics, Inc. ("LogicBio" or the "Company") (NASDAQ: LOGC), in connection with the proposed acquisition of the Company by AstraZeneca Rare Disease ("Alexion") via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $2.07 in cash for each share of LogicBio common stock owned.
Oct 03, 2022 02:24 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nasdaq – OIIM), Coffee Holding Co.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 03, 2022 10:44 am ET
Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca
MILWAUKEE, Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. 
Oct 03, 2022 09:13 am ET
LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders.
Oct 03, 2022 08:30 am ET
Thinking about buying stock in Myovant Sciences, Clovis Oncology, FingerMotion, LogicBio Therapeutics, or Amplify Energy?
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYOV, CLVS, FNGR, LOGC, and AMPY.
Oct 03, 2022 07:15 am ET
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
Oct 03, 2022 07:00 am ET
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
LogicBio acquisition to build on current collaborations and advancements in genomic medicine
Sep 21, 2022 08:30 am ET
LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE
Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet.
Aug 15, 2022 07:05 am ET
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression
May 17, 2022 08:30 am ET
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Tuesday, May 24, 2022.
May 16, 2022 08:30 am ET
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
–FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia
May 11, 2022 08:30 am ET
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
-GeneRide® LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers
May 09, 2022 11:00 am ET
Thinking about buying stock in LogicBio Therapeutics, Rivian Automotive, Lucid Group, Party City, or Nikola Corp?
NEW YORK, May 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LOGC, RIVN, LCID, PRTY, and NKLA.
Mar 23, 2022 04:30 pm ET
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
LEXINGTON, Mass., March 23, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand beginning at 7:00 a.m. ET on March 30, 2022.
Mar 08, 2022 03:05 pm ET
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
LEXINGTON, Mass., March 8, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET.
Mar 04, 2022 03:05 pm ET
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates.
Feb 02, 2022 05:00 am ET
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program
LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update.
Jan 04, 2022 07:00 am ET
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.
Dec 22, 2021 07:00 am ET
LogicBio Therapeutics Provides Business Updates
LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.
Nov 15, 2021 06:00 am ET
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
LEXINGTON, Mass., Nov. 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.
Nov 11, 2021 03:05 pm ET
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences:
Oct 21, 2021 08:00 am ET
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021. The newly presented preclinical data further validate previous research in methylmalonic acidemia (MMA) and highlight selective advantage, a key feature of the GeneRide technology, in two additional indications characterized by intrinsic liver damage, hereditary tyrosinemia t
Oct 18, 2021 08:00 am ET
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
LEXINGTON, Mass., Oct. 18, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children. Early data from the company's Phase 1/2 SUNRISE clinical trial showed measurable levels of albumin-2A, a technology-related biomarker indicating site-specific gene insertion and protein expression. The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing t
Oct 12, 2021 04:05 pm ET
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
LEXINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, to be held from October 19-22, 2021.
Sep 24, 2021 04:05 pm ET
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.
Sep 10, 2021 08:00 am ET
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.
Aug 09, 2021 08:00 am ET
LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
LEXINGTON, Mass., Aug. 9, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.
Jul 08, 2021 07:00 am ET
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.
Jan 07, 2021 07:00 am ET
LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
LEXINGTON, Mass., Jan. 7, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the expansion of the Company's research partnership with Children's Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors for a range of gene therapy and gene editing applications in the treatment of serious diseases of the liver and two other tissues.
Jan 06, 2021 07:00 am ET
LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass., Jan. 6, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET. Mr. Chereau will provide an overview of company operations including development of its proprietary genome editing platform GeneRide and its next-generation synthetic capsids. He will also participate in one-on-one sessions with investors during the virtual conference.
Dec 22, 2020 07:00 am ET
Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer
LEXINGTON, Mass., Dec. 22, 2020 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021.  Matthias Jaffe, the current CFO at LogicBio, will step down at the end of the year and will remain a consultant to the Company during 2021.
Dec 14, 2020 07:00 am ET
LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors
LEXINGTON, Mass., Dec. 14, 2020 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company developing therapies based on advanced gene editing technology and next-generation synthetic capsids, today announced that Daphne Karydas and Jeff Goater have been appointed to the Company's board of directors. 
Nov 12, 2020 04:05 pm ET
LogicBio Therapeutics to Present at Upcoming Investor Conferences
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today announced senior member of management will be presenting at upcoming investor conferences COO Kyle...
Nov 09, 2020 06:30 am ET
LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended September 30,...
Nov 04, 2020 07:45 am ET
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Nov 03, 2020 04:05 pm ET
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the appointment of Mariana Nacht, Ph.D., as chief scientific officer,...
Oct 05, 2020 11:12 am ET
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering...
Oct 01, 2020 09:09 am ET
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering...
Sep 30, 2020 04:01 pm ET
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced that it intends to offer and sell shares of its common stock in an...
Sep 25, 2020 07:48 pm ET
LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy...
Sep 25, 2020 07:47 pm ET
LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines...
Aug 10, 2020 06:35 am ET
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the clinical trial design for the planned Phase 1/2...
Aug 10, 2020 06:30 am ET
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended June 30, 2020,...
Jun 05, 2020 07:00 am ET
LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
LogicBio Therapeutics, Inc. (Nasdaq:  LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020...
May 28, 2020 07:00 am ET
LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the Jefferies Virtual Healthcare...
May 18, 2020 10:28 am ET
LOGC FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Reminds LogicBio Investors of Important Deadline in Securities Class Action - LOGC
NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the "Class Period") of the important May 18, 2020 lead plaintiff deadline in the class action first filed by the firm. The lawsuit seeks to recover damages for LogicBio investors under the federal securities laws.
May 17, 2020 01:00 pm ET
LOGC DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 18, 2020
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of LogicBio Therapeutics, Inc. (“LogicBio” or the Company”) (NASDAQ: LOGC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LogicBio securities between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
May 15, 2020 09:56 am ET
LOGICBIO FINAL DEADLINE MONDAY: ROSEN, A LEADING AND TOP RANKED FIRM, Reminds LogicBio Investors of Important May 18 Deadline in First Filed Securities Class Action Commenced by the Firm – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
May 14, 2020 01:00 pm ET
LOGC DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 18, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of LogicBio Therapeutics, Inc. (“LogicBio” or the Company”) (NASDAQ: LOGC) and certain of its officers, on behalf of...
May 12, 2020 08:17 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
May 11, 2020 04:10 pm ET
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the American Society of...
May 11, 2020 04:05 pm ET
LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results for the quarter ended March 31,...
May 07, 2020 10:28 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
May 05, 2020 07:45 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
May 01, 2020 12:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 28, 2020 11:00 am ET
LOGC & PAYS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 27, 2020 02:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 25, 2020 03:45 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
Apr 23, 2020 11:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 15, 2020 09:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 15, 2020 06:14 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating LogicBio Therapeutics, Inc. (LOGC) for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that it is investigating LogicBio Therapeutics, Inc. (NASDAQ: LOGC) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. LogicBio is a genome editing company th
Apr 15, 2020 04:15 pm ET
ROSEN, A RANKED AND LEADING FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important May 18th Deadline in Securities Class Action – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
Apr 12, 2020 01:20 pm ET
LOGC LOSS NOTICE: ROSEN, A TOP LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors With Large Losses of the May 18th Deadline in Class Action Seeking Recovery of Investor Losses – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for LogicBio investors under the federal securities laws.
Apr 10, 2020 12:22 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 07, 2020 08:00 pm ET
LOGC DEADLINE NOTICE, ROSEN, A TOP LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by Firm; Investors with Large Losses Should Contac
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
Apr 02, 2020 03:06 pm ET
Shareholder Alert: Robbins LLP Reminds Investors LogicBio Therapeutics, Inc. (LOGC) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020. LogicBio is a genome editing company
Apr 01, 2020 07:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of  LogicBio Therapeutics, Inc. – LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 01, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Alpha and Omega Semiconductor, LogicBio, PaySign, and XP and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL), LogicBio Therapeutics,...
Mar 28, 2020 11:41 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, March 28, 2020 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as
Mar 27, 2020 01:17 pm ET
LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Di
NEW YORK, March 27, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against of LogicBio Therapeutics, Inc. ("LogicBio" or the Company") (NASDAQ: LOGC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LogicBio securities between December 3, 2018 and February 10, 2020, inclusive (the "Class Period").   
Mar 26, 2020 12:00 pm ET
LOGC INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of LogicBio Therapeutics, Inc. (“LogicBio” or the Company”) (NASDAQ: LOGC) and certain of its officers, on behalf of...
Mar 25, 2020 06:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cronos Group, Gulfport Energy, Alpha and Omega Semiconductor, and LogicBio Therapeutics and Encourages
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Group, Inc. (NASDAQ: CRON), Gulfport Energy Corporation (NASDAQ: GPOR), Alpha...
Mar 25, 2020 12:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 24, 2020 10:00 am ET
LOGC INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of LogicBio Therapeutics, Inc. (“LogicBio” or the Company”) (NASDAQ: LOGC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LogicBio securities between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 23, 2020 05:00 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead...
Mar 21, 2020 03:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm – LOGC
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”) of the important May 18, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for LogicBio investors under the federal securities laws.
Mar 20, 2020 07:30 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc.
Federman & Sherwood announces that on March 18, 2020, a class action lawsuit was filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc. (NASDAQ: LOGC). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is December 3, 2018 through February 10, 2020.
Mar 20, 2020 03:00 pm ET
LOGC INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
NEW YORK, March 20, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of LogicBio Therapeutics, Inc. ("LogicBio" or the Company") (NASDAQ: LOGC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LogicBio securities between December 3, 2018 and February 10, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/logc.
Mar 20, 2020 12:14 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against LogicBio Therapeutics, Inc. (“LogicBio” or “the Company”) (NASDAQ:
Mar 20, 2020 12:00 pm ET
ROSEN, A LEADING LAW FIRM, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. – LOGC
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the...
Mar 19, 2020 08:02 pm ET
Shareholder Alert: Robbins LLP Announces LogicBio Therapeutics, Inc. (LOGC) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020. LogicBio is a genome editing company that focuses on
Mar 19, 2020 07:08 pm ET
LOGICBIO THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased LogicBio Therapeutics, Inc. (NASDAQ: LOGC) securities between December 3, 2018 and February 10, 2020 (the “Class Period”). Investors have until May 18, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 19, 2020 04:41 pm ET
LOGC LOSS ALERT: ROSEN, A GLOBLLY RECOGNIZED FIRM, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. - LOGC
NEW YORK, March 19, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for LogicBio investors under the federal securities laws.
Mar 19, 2020 04:29 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. (LOGC)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC) in the United States District Court for the District of New Jersey on behalf of those...
Mar 19, 2020 01:08 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against LogicBio Therapeutics, Inc. (“LogicBio” or “the Company”) (NASDAQ:
Mar 19, 2020 11:16 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 18, 2020 05:49 pm ET
EQUITY ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. – LOGC
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for LogicBio investors under the federal securities laws.
Mar 16, 2020 04:05 pm ET
LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for...
Mar 16, 2020 04:05 pm ET
LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that Mark Enyedy has been appointed to its Board of Directors, effective as of...
Mar 02, 2020 02:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Feb 27, 2020 01:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Feb 21, 2020 03:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Feb 19, 2020 06:11 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against LogicBio Therapeutics, Inc. – LOGC
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) resulting from allegations that LogicBio may have issued materially...
Feb 18, 2020 05:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
NEW YORK, Feb. 18, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. ("LogicBio" or the "Company") (NASDAQ: LOGC).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Feb 14, 2020 01:51 pm ET
LOGC LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against LogicBio Therapeutics, Inc. – LOGC
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) resulting from allegations that LogicBio may have issued materially...
Feb 13, 2020 12:12 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or “the Company”) (NASDAQ:
Feb 12, 2020 08:58 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or “the Company”) (NASDAQ:
Feb 11, 2020 06:01 pm ET
EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. – LOGC
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) resulting from allegations that LogicBio may have issued materially misleading business information to the investing public.
Feb 11, 2020 02:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC
Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”) (NASDAQ: LOGC).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Feb 10, 2020 04:05 pm ET
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on...
Jan 10, 2020 07:05 am ET
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has submitted an Investigational New Drug (IND) application with the U.S....
Jan 10, 2020 07:00 am ET
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients today announced a research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to...
Dec 17, 2019 08:00 am ET
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has entered into an exclusive license with Oregon Health & Science...
Nov 12, 2019 08:00 am ET
LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for...
Nov 07, 2019 08:00 am ET
LogicBio Therapeutics to Present at November Conferences
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences: 10th Annual...
Oct 16, 2019 08:00 am ET
LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the European Society of Gene and Cell Therapy...
Oct 09, 2019 04:15 pm ET
Horizon Technology Finance Provides Third Quarter 2019 Portfolio Update
FARMINGTON, Conn., Oct. 9, 2019 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the third quarter ended September 30, 2019.
Sep 26, 2019 08:00 am ET
LogicBio Therapeutics to Present at October Conferences
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences: 2019 Cell &...
Aug 13, 2019 08:00 am ET
LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for...
Jul 16, 2019 08:00 am ET
LogicBio Therapeutics Receives Rare Pediatric Disease Designation for LB-001 for the Treatment of Methylmalonic Acidemia
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease...
Jul 02, 2019 04:05 pm ET
LogicBio Secures Up To $20 Million Debt Facility with Oxford Finance LLC and Horizon Technology Finance
LogicBio Therapeutics, Inc. (Nasdaq: LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the closing of a $20 million secured debt facility with Oxford Finance...
May 30, 2019 08:00 am ET
LogicBio to Present at the Jefferies 2019 Healthcare Conference
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced that Fred Chereau, President and Chief Executive Officer of LogicBio, will present a corporate...
May 14, 2019 08:00 am ET
LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided a corporate update for the first quarter...
Apr 29, 2019 08:00 am ET
LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Apr 22, 2019 08:00 am ET
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced a significant expansion of its leadership team to continue developing its technology platform in...
Apr 01, 2019 08:00 am ET
LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided a corporate update for the fourth quarter...
Feb 25, 2019 07:00 am ET
LogicBio Therapeutics to Present at Upcoming March Conferences
LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced it will present at each of the following upcoming healthcare conferences: 8th Annual SVB Leerink...
Feb 22, 2019 07:00 am ET
LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical...
Dec 06, 2018 08:00 am ET
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its...
Dec 03, 2018 08:00 am ET
LogicBio Reports Third Quarter 2018 Financial Results
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today reported financial results and...
Nov 15, 2018 06:00 am ET
LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors
LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the launch of a partnership to develop new viral vectors with Children’s Medical Research Institute...
Nov 13, 2018 08:00 am ET
LogicBio to Present at the Jefferies 2018 London Healthcare Conference
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today announced that Fred Chereau, President and Chief Executive...
Oct 23, 2018 04:05 pm ET
LogicBio Therapeutics Announces Closing of Initial Public Offering
LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today announced the closing of its initial public offering of...
Oct 22, 2018 04:00 pm ET
Chardan Serves as Lead Manager for LogicBio Therapeutics
NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.